Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Income from Continuing Operations readings, the most recent being 2133000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 242.11% to 2133000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 2809000.0, a 1651.93% decrease, with the full-year FY2025 number at 9741000.0, down 180.8% from a year prior.
  • Income from Continuing Operations hit 2133000.0 in Q4 2025 for Fennec Pharmaceuticals, up from 623000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 12906000.0 in Q1 2024 to a low of 7994000.0 in Q3 2022.
  • Median Income from Continuing Operations over the past 5 years was 3917000.0 (2021), compared with a mean of 2891368.42.
  • The widest YoY moves for Income from Continuing Operations: up 316.58% in 2024, down 222.47% in 2024.
  • Fennec Pharmaceuticals' Income from Continuing Operations stood at 4215000.0 in 2021, then crashed by 63.58% to 6895000.0 in 2022, then soared by 62.03% to 2618000.0 in 2023, then skyrocketed by 42.67% to 1501000.0 in 2024, then surged by 242.11% to 2133000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 2133000.0 (Q4 2025), 623000.0 (Q3 2025), and 3155000.0 (Q2 2025) per Business Quant data.